Synopsis
Synopsis
0
CEP/COS
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 2-methoxyethyl-3-phenyl-2-propen-1-yl-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylate
2. Cilnidipine, (+)-isomer
3. Cilnidipine, (-)-isomer
4. Frc 8653
5. Frc-8653
1. 132203-70-4
2. Cinalong
3. Atelec
4. Siscard
5. Frc-8653
6. Frc 8653
7. 3-cinnamyl 5-(2-methoxyethyl) 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
8. Cilnidipine [inn]
9. Chebi:31399
10. Cilnidipine, (+)-
11. Cilnidipine, (-)-
12. (+-)-(e)-cinnamyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate
13. 97t5az1jip
14. 4lnu2su262
15. S85436zg85
16. 2-methoxyethyl (2e)-3-phenylprop-2-en-1-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
17. Ncgc00162150-01
18. Cinaldipine
19. (+)-frc-8653
20. (-)-frc-8653
21. Dsstox_cid_26309
22. Dsstox_rid_81530
23. Dsstox_gsid_46309
24. (e)-cinnamyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate
25. 3,5-pyridinedicarboxylic Acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-methoxyethyl 3-phenyl-2-propenyl Ester, (e)-(+)-
26. 3,5-pyridinedicarboxylic Acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-methoxyethyl 3-phenyl-2-propenyl Ester, (e)-(-)-
27. Atelec (tn)
28. Cas-132203-70-4
29. Sr-05000001454
30. 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic Acid 2-methoxyethyl (2e)-3-phenyl-2-propenyl Ester
31. Unii-97t5az1jip
32. 3,5-pyridinedicarboxylic Acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 3-(2-methoxyethyl) 5-((2e)-3-phenyl-2-propen-1-yl) Ester
33. 3,5-pyridinedicarboxylic Acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 3-(2-methoxyethyl) 5-[(2e)-3-phenyl-2-propen-1-yl] Ester
34. Cilnidipine- Bio-x
35. Mfcd00865853
36. Cilnidipine [mi]
37. Cilnidipine [jan]
38. Cilnidipine (jp17/inn)
39. Cilnidipine [mart.]
40. Unii-4lnu2su262
41. Schembl25550
42. Cilnidipine [who-dd]
43. 3-o-(2-methoxyethyl) 5-o-[(e)-3-phenylprop-2-enyl] 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
44. Chembl452076
45. Gtpl7767
46. Dtxsid0046309
47. Unii-s85436zg85
48. Chebi:91506
49. Hms2089j07
50. Hms3261e06
51. Hms3413l13
52. Hms3677l13
53. Hms3715n17
54. Hms3884k09
55. Bcp22689
56. Tox21_112001
57. Tox21_500422
58. Ac-270
59. Bdbm50101813
60. S1293
61. Stk623341
62. Akos005558085
63. Tox21_112001_1
64. Ccg-221188
65. Ccg-221726
66. Cilnidipine, >=98% (hplc), Powder
67. Cs-1133
68. Db09232
69. Ks-1294
70. Lp00422
71. Sdccgsbi-0633712.p001
72. Ncgc00162150-02
73. Ncgc00162150-03
74. Ncgc00162150-04
75. Ncgc00162150-16
76. Ncgc00261107-01
77. 3,5-pyridinedicarboxylic Acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-methoxyethyl 3-phenyl-2-propenyl Ester, (e)-(+-)-
78. Bc164309
79. Hy-17404
80. Ls-15175
81. Sw219784-1
82. D01173
83. T70209
84. Ab01274755-01
85. Ab01274755-02
86. Ab01274755_03
87. Frc-8653; Frc 8653; Frc8653
88. 203c704
89. Q731525
90. J-006141
91. Sr-05000001454-1
92. Sr-05000001454-2
93. Brd-a07875874-001-01-6
94. F2173-0669
95. (+/-)-(e)-cinnamyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate
96. 102106-21-8
97. 118934-76-2
98. 118934-77-3
99. 132295-21-7
100. 132338-87-5
101. 2-methoxyethyl (2e)-3-phenyl-2-propenyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate
102. O3-(2-methoxyethyl) O5-(3-phenylprop-2-enyl) 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
| Molecular Weight | 492.5 g/mol |
|---|---|
| Molecular Formula | C27H28N2O7 |
| XLogP3 | 4.4 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 11 |
| Exact Mass | 492.18965124 g/mol |
| Monoisotopic Mass | 492.18965124 g/mol |
| Topological Polar Surface Area | 120 Ų |
| Heavy Atom Count | 36 |
| Formal Charge | 0 |
| Complexity | 896 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 1 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Cilnidipine is indicated for the management of hypertension for end-organ protection. It is reported to be useful in elderly patients and in those with diabetes and albuminuria. Cilnidipine has been increasingly used in patients with chronic kidney disease Hypertension is the term used to describe the presence of high blood pressure. The blood pressure is generated by the force of the blood pumped from the heart against the blood vessels. Thus hypertension is caused when there is too much pressure on the blood vessels and this effect can damage the blood vessel.
Administration of cilnidipine has been shown to present an antisympathetic profile in vitro and in vivo. It decreases blood pressure safely and effectively without excessive blood pressure reduction or tachycardia.
Calcium Channel Blockers
A class of drugs that act by selective inhibition of calcium influx through cellular membranes. (See all compounds classified as Calcium Channel Blockers.)
C - Cardiovascular system
C08 - Calcium channel blockers
C08C - Selective calcium channel blockers with mainly vascular effects
C08CA - Dihydropyridine derivatives
C08CA14 - Cilnidipine
Absorption
Cilnidipine presents a very rapid absorption with a maximum peaked concentration after 2 hours. Its distribution tends to be higher in the liver as well as in kidneys, plasma and other tissues. Cilnidipine does not present a high accumulation in the tissue after repeated oral administration. Cilnidipine is reported to present very low bioavailability determined to be approximately 13%. This low bioavailability is suggested to be due to its low aqueous solubility and high permeability. Hence, efforts have been made in order to find an innovative formulation that can significantly improve the bioavailability of this drug. One of these formulations corresponds to the generation of polymeric nanoparticles which enhance the bioavailability by 2.5-3-fold.
Route of Elimination
Cilnidipine gets eliminated through the urine in a proportion of 20% of the administered dose and 80% is eliminated by the feces.
Volume of Distribution
Drugs on the group of dihydropyridines such as cilnidipine tend to have a large volume of distribution.
Cilnidipine is metabolized by both liver and kidney. It is rapidly metabolized by liver microsomes by a dehydrogenation process. The major enzymatic isoform involved in cilnidipine dehydrogenation of the dihydropyridine ring is CYP3A.
The half-life of the hypotensive effect for cilnidipine is of about 20.4 min.
Cilnidipine acts on the L-type calcium channels of blood vessels by blocking the incoming calcium and suppressing the contraction of blood vessels, thereby reducing blood pressure. Cilnidipine also works on the N-type calcium channel located at the end of the sympathetic nerve, inhibiting the emission of norepinephrine and suppressing the increase in stress blood pressure.
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
Market Place
ABOUT THIS PAGE
99
PharmaCompass offers a list of Cilnidipine API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Cilnidipine manufacturer or Cilnidipine supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Cilnidipine manufacturer or Cilnidipine supplier.
PharmaCompass also assists you with knowing the Cilnidipine API Price utilized in the formulation of products. Cilnidipine API Price is not always fixed or binding as the Cilnidipine Price is obtained through a variety of data sources. The Cilnidipine Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Atelec manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Atelec, including repackagers and relabelers. The FDA regulates Atelec manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Atelec API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Atelec manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Atelec supplier is an individual or a company that provides Atelec active pharmaceutical ingredient (API) or Atelec finished formulations upon request. The Atelec suppliers may include Atelec API manufacturers, exporters, distributors and traders.
click here to find a list of Atelec suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Atelec DMF (Drug Master File) is a document detailing the whole manufacturing process of Atelec active pharmaceutical ingredient (API) in detail. Different forms of Atelec DMFs exist exist since differing nations have different regulations, such as Atelec USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Atelec DMF submitted to regulatory agencies in the US is known as a USDMF. Atelec USDMF includes data on Atelec's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Atelec USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Atelec suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Atelec Drug Master File in Japan (Atelec JDMF) empowers Atelec API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Atelec JDMF during the approval evaluation for pharmaceutical products. At the time of Atelec JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Atelec suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Atelec Drug Master File in Korea (Atelec KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Atelec. The MFDS reviews the Atelec KDMF as part of the drug registration process and uses the information provided in the Atelec KDMF to evaluate the safety and efficacy of the drug.
After submitting a Atelec KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Atelec API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Atelec suppliers with KDMF on PharmaCompass.
A Atelec written confirmation (Atelec WC) is an official document issued by a regulatory agency to a Atelec manufacturer, verifying that the manufacturing facility of a Atelec active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Atelec APIs or Atelec finished pharmaceutical products to another nation, regulatory agencies frequently require a Atelec WC (written confirmation) as part of the regulatory process.
click here to find a list of Atelec suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Atelec as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Atelec API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Atelec as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Atelec and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Atelec NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Atelec suppliers with NDC on PharmaCompass.
Atelec Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Atelec GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Atelec GMP manufacturer or Atelec GMP API supplier for your needs.
A Atelec CoA (Certificate of Analysis) is a formal document that attests to Atelec's compliance with Atelec specifications and serves as a tool for batch-level quality control.
Atelec CoA mostly includes findings from lab analyses of a specific batch. For each Atelec CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Atelec may be tested according to a variety of international standards, such as European Pharmacopoeia (Atelec EP), Atelec JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Atelec USP).
